← Leaderboards
Guang-Yu Yang
Northwestern University
$9,518,287
Attributed
$9,518,287
Total exposure
8
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,518,287 · 8
By mechanism
R01$8,766,714 · 6
P30$419,373 · 1
R21$332,200 · 1
Top collaborators
No co-investigators on record.
Most similar at Northwestern University
Same institution · by research overlap
- Seema Ahsan Khan$17,558,735
- Raymond Bergan$2,708,649
Others in their field
Top investigators on “Mouse Model”
- Dennis R. Burton · Scripps Research Institute$280,661,242
- David Heimbrook · Leidos Biomedical Research, Inc.$84,491,283
- Kc Kent Lloyd · University Of California At Davis$74,285,556
- Alan F Horwitz · University Of Virginia Charlottesville$73,668,592
- Stanley B Prusiner · University Of California San Francisco$61,905,394
- Ed Lein · Allen Institute$59,425,748
Research focus
Mouse ModelCarcinogenesisInflammationInhibitor/AntagonistKnock-OutAnti-Inflammatory AgentsTumorAnimalsAnti-InflammatoryArachidonic AcidsSignal TransductionRisk FactorsInflammatoryPreventionChemopreventive AgentBaseEnzymesPrevention StrategyMutantEpoxide HydrolaseMalignant Neoplasm Of PancreasNf-Kappa BEventIn Vitro
Grant awards (30)
Role of epoxy fatty acids - soluble epoxide hydrolase axis in intestinal mucosal barrier defense$565,079
R01 · FY2025 · DK · contact PI
Role of epoxy fatty acids - soluble epoxide hydrolase axis in intestinal mucosal barrier defense$667,022
R01 · FY2024 · DK · contact PI
Mouse Histology and Phenotyping Laboratory Shared Resource$141,304
P30 · FY2024 · CA · contact PI
Mouse Histology and Phenotyping Laboratory Shared Resource$141,304
P30 · FY2023 · CA · contact PI
Mouse Histology and Phenotyping Laboratory Shared Resource$136,765
P30 · FY2022 · CA · contact PI
Omega-3 derived epoxy fatty acids and sEH in pancreatitis-induced carcinogenesis$475,045
R01 · FY2019 · DK · contact PI
Omega-3 derived epoxy fatty acids and sEH in pancreatitis-induced carcinogenesis$481,371
R01 · FY2018 · DK · contact PI
Omega-3 derived epoxy fatty acids and sEH in pancreatitis-induced carcinogenesis$481,828
R01 · FY2017 · DK · contact PI
Inhibition of pancreatic carcinogenesis via targeting c-Raf and sEH$320,338
R01 · FY2017 · CA · contact PI
Omega-3 derived epoxy fatty acids and sEH in pancreatitis-induced carcinogenesis$500,335
R01 · FY2016 · DK · contact PI
Aldo-keto reductase family 1 member B10 AKR1B10 in pancreatic carcinogenesis$320,525
R01 · FY2016 · CA · contact PI
Inhibition of pancreatic carcinogenesis via targeting c-Raf and sEH$320,338
R01 · FY2016 · CA · contact PI
Aldo-keto reductase family 1 member B10 AKR1B10 in pancreatic carcinogenesis$320,525
R01 · FY2015 · CA · contact PI
Inhibition of pancreatic carcinogenesis via targeting c-Raf and sEH$320,338
R01 · FY2015 · CA · contact PI
Aldo-keto reductase family 1 member B10 AKR1B10 in pancreatic carcinogenesis$310,909
R01 · FY2014 · CA · contact PI
Inhibition of pancreatic carcinogenesis via targeting c-Raf and sEH$310,728
R01 · FY2014 · CA · contact PI
Inhibition of pancreatic carcinogenesis via targeting c-Raf and sEH$333,963
R01 · FY2013 · CA · contact PI
Aldo-keto reductase family 1 member B10 AKR1B10 in pancreatic carcinogenesis$304,278
R01 · FY2013 · CA · contact PI
Aldo-keto reductase family 1 member B10 AKR1B10 in pancreatic carcinogenesis$330,975
R01 · FY2012 · CA · contact PI
Soluble epoxide hydrolase as a novel target of colitis-induced carcinogenesis$304,078
R01 · FY2012 · CA · contact PI
Soluble epoxide hydrolase as a novel target of colitis-induced carcinogenesis$303,873
R01 · FY2011 · CA · contact PI
Soluble epoxide hydrolase as a novel target of colitis-induced carcinogenesis$313,077
R01 · FY2010 · CA · contact PI
Soluble epoxide hydrolase as a novel target of colitis-induced carcinogenesis$326,169
R01 · FY2009 · CA · contact PI
Ulcerative colitis-associated cancer and its prevention$216,840
R01 · FY2008 · CA · contact PI
HMG-CoA reductase inhibitor, tea polyphenols and pancreatic cancer prevention$211,400
R21 · FY2008 · CA · contact PI
Ulcerative colitis-associated cancer and its prevention$216,840
R01 · FY2007 · CA · contact PI
HMG-CoA reductase inhibitor, tea polyphenols and pancreatic cancer prevention$120,800
R21 · FY2007 · CA · contact PI
Ulcerative colitis-associated cancer and its prevention$233,081
R01 · FY2006 · CA · contact PI
Ulcerative colitis-associated cancer and its prevention$238,690
R01 · FY2005 · CA
Ulcerative colitis-associated cancer and its prevention$250,469
R01 · FY2004 · CA